Arguedas Adriano, Emparanza Paz, Schwartz Richard H, Soley Carolina, Guevara Silvia, de Caprariis Pascal J, Espinoza Gabriela
Instituto de Atención Pediátrica, San José, Costa Rica.
Pediatr Infect Dis J. 2005 Feb;24(2):153-61. doi: 10.1097/01.inf.0000151024.11703.4a.
High dose amoxicillin is recommended for the initial treatment of children with acute otitis media (AOM), particularly patients at risk for having drug-resistant Streptococcus pneumoniae. Single dose azithromycin (30 mg/kg) is considered an alternative agent for the treatment of AOM.
To compare the clinical efficacy and safety of single dose azithromycin with that of high dose amoxicillin among children with uncomplicated AOM.
This was a double blind, double dummy, multinational, clinical trial in which children (6-30 months of age) with AOM were randomized to treatment with single dose azithromycin (30 mg/kg) or high dose amoxicillin (90 mg/kg/d, in 2 divided doses) for 10 days. Tympanocentesis was performed at baseline and clinical responses were assessed at days 12-14 (end of therapy) and at days 25-28 (end of study).
The study enrolled 313 patients, and 83% of the patients were < or =2 years of age. A total of 158 patients in the azithromycin group and 154 in the amoxicillin group were considered clinical modified intent-to-treat patients. A middle ear pathogen was detected for 212 patients (68%). Haemophilus influenzae was the most common pathogen (isolated for 96 patients), followed by S. pneumoniae (92 patients), Moraxella catarrhalis (23 patients) and Streptococcus pyogenes (23 patients). beta-Lactamase production was observed for 17% of H. influenzae isolates and 100% of M. catarrhalis isolates. Thirty-five (38%) S. pneumoniae isolates were penicillin-nonsusceptible and 24 (26%) isolates were macrolide-resistant. At the end of therapy, clinical success rates for azithromycin and amoxicillin were comparable for all patients (84 and 84%, respectively) and for children < or =2 years of age (82 and 82%, respectively). At the end of therapy and end of study, clinical efficacies among all microbiologic modified intent-to-treat evaluable subjects were comparable for patients treated with azithromycin (80%) and patients treated with amoxicillin (83%). The rates of treatment-related adverse events for azithromycin and amoxicillin were 20% and 29%, respectively (P = 0.064). Diarrhea was more common in the amoxicillin group than in the azithromycin group (17.5 and 8.2%, respectively) (P = 0.017). Compliance, defined as completion of > or =80% of the study medication, was higher in the azithromycin group (100%) than in the amoxicillin group (90%) (P = 0.001).
In this study, single dose azithromycin was as effective as high dose amoxicillin for the treatment of children with AOM, whereas rates of adverse events were lower and compliance improved with the simplified single dose regimen.
高剂量阿莫西林被推荐用于急性中耳炎(AOM)患儿的初始治疗,尤其是有感染耐青霉素肺炎链球菌风险的患者。单剂量阿奇霉素(30mg/kg)被认为是治疗AOM的替代药物。
比较单剂量阿奇霉素与高剂量阿莫西林治疗非复杂性AOM患儿的临床疗效和安全性。
这是一项双盲、双模拟、多中心临床试验,将患有AOM的儿童(6 - 30个月龄)随机分为接受单剂量阿奇霉素(30mg/kg)或高剂量阿莫西林(90mg/kg/d,分2次给药)治疗10天。在基线时进行鼓膜穿刺,并在第12 - 14天(治疗结束时)和第25 - 28天(研究结束时)评估临床反应。
该研究共纳入313例患者,83%的患者年龄小于或等于2岁。阿奇霉素组有158例患者,阿莫西林组有154例患者被视为临床改良意向性治疗患者。212例患者(68%)检测到中耳病原体。流感嗜血杆菌是最常见的病原体(96例患者分离到),其次是肺炎链球菌(92例患者)、卡他莫拉菌(23例患者)和化脓性链球菌(23例患者)。17%的流感嗜血杆菌分离株和1oo%的卡他莫拉菌分离株产β-内酰胺酶。35株(38%)肺炎链球菌分离株对青霉素不敏感,24株(26%)分离株对大环内酯类耐药。治疗结束时,阿奇霉素和阿莫西林对所有患者的临床成功率相当(分别为84%和84%),对年龄小于或等于2岁的儿童也相当(分别为82%和82%)。在治疗结束时和研究结束时,在所有微生物改良意向性治疗可评估受试者中,接受阿奇霉素治疗的患者(80%)和接受阿莫西林治疗的患者(83%)临床疗效相当。阿奇霉素和阿莫西林治疗相关不良事件发生率分别为20%和29%(P = 0.064)。腹泻在阿莫西林组比阿奇霉素组更常见(分别为17.5%和8.2%)(P = 0.017)。依从性定义为完成≥80%的研究药物治疗,阿奇霉素组(100%)高于阿莫西林组(90%)(P = 0.001)。
在本研究中,单剂量阿奇霉素治疗AOM患儿与高剂量阿莫西林同样有效,而简化的单剂量方案不良事件发生率更低且依从性更好。